← Edwards Lifesciences Corp
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Net Income (Loss) Attributable to Parent | $569.5m | $583.6m | $722.2m | $1.0b | $823.4m | $1.5b | $1.5b | $1.4b | $4.2b | $1.1b | |
| Net Income (Loss) Available to Common Stockholders, Basic | $569.5m | $583.6m | $722.2m | $1.0b | $823.4m | $1.5b | $1.5b | $1.4b | $4.2b | $1.1b | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | — | — | $1.4b | $4.2b | $1.1b | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | — | — | — | $1.4b | $1.1b | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | — | — | — | $1.4b | $1.1b | |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | — | — | — | $2.8b | $13.4m | |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | — | — | — | $2.8b | $13.4m | |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | — | — | — | — | — | ($3.0m) | ($4.9m) | ($4.1m) | |
| Depreciation, Depletion and Amortization | $71.2m | $81.9m | $77.4m | $89.3m | $107.2m | $134.8m | $139.6m | $144.9m | $155.2m | $156.6m | |
| Depreciation | $63.6m | $74.1m | $74.9m | $84.7m | $101.8m | $127.0m | $133.9m | $138.9m | $137.6m | $148.2m | |
| Amortization of Intangible Assets | $7.6m | $7.8m | $2.5m | $4.6m | $5.4m | $7.7m | $5.7m | $6.1m | $5.6m | $8.4m | |
| Deferred Income Tax Expense (Benefit) | ($24.5m) | $27.1m | ($21.2m) | $10.5m | ($52.2m) | ($44.0m) | ($250.9m) | ($262.0m) | ($162.8m) | ($65.8m) | |
| Share-based Payment Arrangement, Noncash Expense | $56.9m | $61.6m | $71.0m | $81.3m | $92.6m | $109.3m | $126.8m | $139.4m | $162.3m | $158.1m | |
| Share-based Payment Arrangement, Expense | $56.9m | $61.6m | $71.0m | $81.3m | $92.6m | $109.3m | $126.8m | $139.4m | $145.6m | $157.9m | |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | $700k | — | — | — | — | — | |
| Impairment of Intangible Assets, Finite-lived | — | — | — | — | $0 | $4.0m | $55.1m | $0 | $0 | $40.0m | |
| Gain (Loss) on Disposition of Business | — | — | — | — | — | — | — | — | $3.3b | $33.9m | |
| Income Tax Expense (Benefit) | $168.4m | $451.3m | $39.2m | $119.6m | $93.3m | $198.9m | $245.5m | $198.7m | $152.1m | $216.9m | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $19.8m | $20.4m | |
| Other Nonoperating Income (Expense) | ($4.9m) | ($8.2m) | $4.0m | $8.2m | $11.5m | $12.7m | $2.6m | $14.4m | $68.9m | $7.2m | |
| Changes in operating assets and liabilities: | |||||||||||
| Additional Financial Items | |||||||||||
| Increase (Decrease) in Inventories | $65.6m | $124.0m | $65.7m | $105.4m | $120.6m | ($19.0m) | $213.4m | $289.0m | $256.1m | ($50.7m) | |
| Proceeds from Stock Options Exercised | — | $77.6m | $103.7m | $110.4m | $79.2m | $82.2m | $64.8m | $83.4m | $90.6m | $89.2m | |
| Foreign Currency Transaction Gain (Loss), before Tax | ($500k) | ($5.4m) | $6.7m | $5.9m | $12.3m | $5.0m | ($1.2m) | $10.5m | $7.1m | $700k | |
| Gain (Loss) on Investments | — | — | — | — | — | — | ($51.5m) | ($100k) | $5.2m | — | |
| Gain (Loss) Related to Litigation Settlement | $0 | — | — | — | — | — | — | — | — | — | |
| Goodwill | $626.1m | $1.1b | $1.1b | $1.2b | $1.2b | $1.2b | $1.2b | $1.3b | $1.8b | $1.8b | |
| Insured Event, Gain (Loss) | — | — | — | — | — | — | $3.8m | $0 | $0 | — | |
| Inventory Write-down | — | — | — | $73.1m | $0 | $0 | — | — | — | — | |
| Investment Income, Interest | $10.8m | $20.3m | $32.0m | $32.2m | $23.4m | $17.4m | $35.5m | $67.2m | $120.3m | $168.8m | |
| Nonoperating Income (Expense) | — | — | — | — | — | — | — | — | $169.4m | $8.7m | |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment | — | — | — | — | — | — | — | — | ($1.2m) | ($400k) | |
| Other Operating Income (Expense), Net | — | — | $0 | $0 | — | — | — | — | $300k | $67.2m | |
| Net Cash Provided by (Used in) Operating Activities | $704.4m | $1.0b | $926.8m | $1.2b | $1.1b | $1.7b | $1.2b | $895.8m | $542.3m | $1.6b | |
| Cash flows from investing activities: | |||||||||||
| Payments to Acquire Property, Plant, and Equipment | $176.1m | $168.1m | $238.7m | $254.4m | $407.0m | $325.8m | $244.6m | $253.0m | $252.4m | $260.2m | |
| Payments to Acquire Businesses, Net of Cash Acquired | $0 | $192.9m | $0 | $100.2m | — | — | — | — | — | — | |
| Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net | — | — | — | — | — | — | $0 | $0 | $55.0m | $0 | |
| Payments for (Proceeds from) Other Investing Activities | $1.2m | ($800k) | ($5.2m) | $24.0m | $12.1m | $44.4m | $28.8m | $12.5m | $72.9m | $7.4m | |
| Net Cash Provided by (Used in) Investing Activities | ($211.7m) | ($647.2m) | $76.7m | ($595.8m) | ($531.1m) | ($1.7b) | $252.3m | $173.8m | $2.3b | ($712.9m) | |
| Cash flows from financing activities: | |||||||||||
| Proceeds from Issuance of Long-term Debt | $253.5m | $994.7m | $688.0m | $18.9m | $16.2m | $5.2m | $0 | $0 | — | — | |
| Payments for Repurchase of Common Stock | $662.3m | $763.3m | $795.5m | $263.3m | $625.4m | $512.8m | $1.7b | $879.6m | $1.2b | $893.4m | |
| Proceeds from (Payments for) Other Financing Activities | $4.1m | $0 | ($300k) | ($2.8m) | ($1.2m) | ($300k) | ($3.6m) | ($1.0m) | ($3.1m) | ($3.8m) | |
| Net Cash Provided by (Used in) Financing Activities | ($268.5m) | ($473.2m) | ($1.1b) | ($115.6m) | ($486.9m) | ($356.3m) | ($1.6b) | ($711.0m) | ($983.0m) | ($956.8m) | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | $7.9m | ($6.5m) | ($3.0m) | ($20.5m) | $13.9m | $19.2m | $16.8m | $38.6m | ($44.8m) | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | $7.9m | ($6.5m) | $465.0m | $15.8m | ($332.8m) | ($94.8m) | $375.4m | $1.9b | ($119.3m) | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | $7.9m | ($6.5m) | $1.2b | $1.2b | $867.4m | $772.6m | $1.1b | $3.1b | $2.9b | |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | $30.1m | $19.9m | $19.9m | $20.2m | $19.3m | $19.9m | $19.6m | $20.2m | |
| Income Taxes Paid, Net | — | — | — | — | — | — | — | — | — | $490.4m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.